| |
Latest 10 SEC filings (by transaction date) for SNSE within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Feb 16/24 | Feb 15/24 | van der Horst Edward | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 90,102 | |
Feb 16/24 | Feb 15/24 | van der Horst Edward | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 125,000 | |
Feb 16/24 | Feb 15/24 | van der Horst Edward | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -2,843 | $0.790 |
Feb 16/24 | Feb 15/24 | Celebi John | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 165,889 | |
Feb 16/24 | Feb 15/24 | Celebi John | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 315,000 | |
Feb 16/24 | Feb 15/24 | Celebi John | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -5,891 | $0.790 |
Feb 16/24 | Feb 15/24 | Colgan Erin | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 94,128 | |
Feb 16/24 | Feb 15/24 | Colgan Erin | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 125,000 | |
Feb 16/24 | Feb 15/24 | Colgan Erin | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -3,627 | $0.790 |
Nov 2/23 | Nov 1/23 | Krebs Stephanie | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 125,000 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for SNSE within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Feb 16/24 | Feb 15/24 | van der Horst Edward | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 90,102 | |
Feb 16/24 | Feb 15/24 | van der Horst Edward | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 125,000 | |
Feb 16/24 | Feb 15/24 | van der Horst Edward | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -2,843 | $0.790 |
Feb 16/24 | Feb 15/24 | Celebi John | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 165,889 | |
Feb 16/24 | Feb 15/24 | Celebi John | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 315,000 | |
Feb 16/24 | Feb 15/24 | Celebi John | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -5,891 | $0.790 |
Feb 16/24 | Feb 15/24 | Colgan Erin | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 94,128 | |
Feb 16/24 | Feb 15/24 | Colgan Erin | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 125,000 | |
Feb 16/24 | Feb 15/24 | Colgan Erin | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -3,627 | $0.790 |
Nov 2/23 | Nov 1/23 | Krebs Stephanie | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 125,000 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Cerevel Therapeutics Hold (OQ:CERE) |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |